News
Analyst Ratings For Axsome Therapeutics
10 Apr 24
Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Maintains $190 Price Target
2 Apr 24
News, Price Target, Analyst Ratings
Mizuho Maintains Buy on Axsome Therapeutics, Raises Price Target to $109
28 Mar 24
News, Price Target, Analyst Ratings
Truist Securities Maintains Buy on Axsome Therapeutics, Maintains $150 Price Target
26 Mar 24
News, Price Target, Analyst Ratings
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
26 Mar 24
News, Price Target, Small Cap, Markets, Analyst Ratings, Trading Ideas
RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $128
26 Mar 24
News, Price Target, Analyst Ratings
Citigroup Maintains Buy on Axsome Therapeutics, Raises Price Target to $127
26 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $190
26 Mar 24
News, Price Target, Analyst Ratings
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
25 Mar 24
Biotech, Equities, Large Cap, News, Health Care, General
Axsome Therapeutics' AXS-12 (Reboxetine) Achieved The Primary Endpoint And Significantly Reduced The Frequency Of Cataplexy Attacks As Compared To Placebo In Narcolepsy Patients In SYMPHONY Phase 3 Trial
25 Mar 24
Biotech, News, Health Care, General
Baird Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $108
19 Mar 24
News, Price Target, Initiation, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
4 Mar 24
News, Price Target, Reiteration, Analyst Ratings
What Analysts Are Saying About Axsome Therapeutics Stock
27 Feb 24
Analyst Ratings
Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $108
27 Feb 24
News, Price Target, Analyst Ratings
Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $125
21 Feb 24
News, Price Target, Analyst Ratings
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $123
21 Feb 24
News, Price Target, Analyst Ratings
Cantor Fitzgerald Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $103
21 Feb 24
News, Price Target, Analyst Ratings
CORRECTION: Axsome Therapeutics Q4 Adjusted EPS $(0.73) Beats $(1.15) Estimate, Sales $71.53M Beat $67.69M Estimate
20 Feb 24
Earnings, News
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
20 Feb 24
Biotech, Earnings, News, Health Care, Movers, General
Press releases
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
17 Apr 24
News, Legal, Press Releases
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
15 Apr 24
News, Press Releases
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
12 Apr 24
News, Legal, Press Releases
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
3 Apr 24
News, Legal, Press Releases
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
25 Mar 24
News, Legal, Press Releases
Thinking about trading options or stock in Arm Holdings, UiPath, Dell Technologies, Digital World Acquisition, or Axsome Therapeutics?
25 Mar 24
Opinion, Press Releases
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
25 Mar 24
Health Care, Press Releases, General
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
25 Mar 24
News, Health Care, Press Releases
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
27 Feb 24
News, Press Releases